BIOLQ (Biolase) Beneish M-Score: 0.00 (As of Jun. 25, 2026)

What is Biolase Beneish M-Score?

Biolase BIOLQ -99.00% 16 Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus rates BIOLQ with a GF Score™ of 16/100.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Biolase's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Biolase was 0.00. The lowest was 0.00. And the median was 0.00.

Biolase Beneish M-Score Related Terms

Biolase Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Biolase's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biolase Beneish M-Score Chart

Biolase Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beneish M-Score

Get a 7-Day Free Trial

-3.40

-3.64

-2.54

-2.13

-3.43

Biolase Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Beneish M-Score	Get a 7-Day Free Trial															-3.49	-3.43	-3.22	-3.81	-3.08

BIOLQ vs OPGN, AFIB, ABT: Beneish M-Score Comparison

For the Medical Devices subindustry, Biolase's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biolase Beneish M-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Biolase's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Biolase's Beneish M-Score falls into.

Save Embed

16GF Score

Biolase Inc BIOLQ

Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Biolase Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Biolase for today is based on a combination of the following eight different indices:

-4.84

0.92 * DSRI

0.528 * GMI

0.404 * AQI

0.892 * SGI

0.115 * DEPI

-4.84

0.92 * 0.8691

0.528 * 0.9809

0.404 * 1.4179

0.892 * 0.9256

0.115 * 0.6237

0.172 * SGAI

4.679 * TATA

0.327 * LVGI

0.172 * 0.8346

4.679 * -0.093315

0.327 * 1.3774

-3.08

This Year (Sep24) TTM:

Last Year (Sep23) TTM:

Total Receivables was $3.53 Mil.
Revenue was 10.85 + 11.555 + 10.131 + 13.49 = $46.03 Mil.
Gross Profit was 4.382 + 4.609 + 3.336 + 3.524 = $15.85 Mil.
Total Current Assets was $19.43 Mil.
Total Assets was $27.24 Mil.
Property, Plant and Equipment(Net PPE) was $4.63 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.62 Mil.
Selling, General, & Admin. Expense(SGA) was $24.45 Mil.
Total Current Liabilities was $30.86 Mil.
Long-Term Debt & Capital Lease Obligation was $0.21 Mil.
Net Income was -1.428 + -2.798 + -6.485 + -5.326 = $-16.04 Mil.
Non Operating Income was -0.116 + 1.028 + -1.318 + 0.338 = $-0.07 Mil.
Cash Flow from Operations was -4.472 + -0.734 + -5.938 + -2.283 = $-13.43 Mil.

Total Receivables was $4.39 Mil.
Revenue was 10.921 + 14.286 + 10.467 + 14.051 = $49.73 Mil.
Gross Profit was 3.746 + 6.118 + 3.337 + 3.596 = $16.80 Mil.
Total Current Assets was $27.78 Mil.
Total Assets was $38.75 Mil.
Property, Plant and Equipment(Net PPE) was $7.77 Mil.
Depreciation, Depletion and Amortization(DDA) was $2.26 Mil.
Selling, General, & Admin. Expense(SGA) was $31.64 Mil.
Total Current Liabilities was $19.78 Mil.
Long-Term Debt & Capital Lease Obligation was $12.30 Mil.

1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI	=	(Receivables_t / Revenue_t)	/	(Receivables_t-1 / Revenue_t-1)
	=	(3.53 / 46.026)	/	(4.388 / 49.725)
	=	0.076696	/	0.088245
	=	0.8691

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI	=	GrossMargin_t-1	/	GrossMargin_t
	=	(GrossProfit_t-1 / Revenue_t-1)	/	(GrossProfit_t / Revenue_t)
	=	(16.797 / 49.725)	/	(15.851 / 46.026)
	=	0.337798	/	0.344392
	=	0.9809

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI	=	(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t)	/	(1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
	=	(1 - (19.428 + 4.627) / 27.241)	/	(1 - (27.782 + 7.767) / 38.745)
	=	0.116956	/	0.082488
	=	1.4179

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI	=	Sales_t	/	Sales_t-1
	=	Revenue_t	/	Revenue_t-1
	=	46.026	/	49.725
	=	0.9256

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI	=	(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))	/	(Depreciation_t / (Depreciaton_t + PPE_t))
	=	(2.261 / (2.261 + 7.767))	/	(2.62 / (2.62 + 4.627))
	=	0.225469	/	0.361529
	=	0.6237

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI	=	(SGA_t / Sales_t)	/	(SGA_t-1 /Sales_t-1)
	=	(24.445 / 46.026)	/	(31.643 / 49.725)
	=	0.531113	/	0.63636
	=	0.8346

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI	=	((LTD_t + CurrentLiabilities_t) / TotalAssets_t)	/	((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
	=	((0.211 + 30.859) / 27.241)	/	((12.302 + 19.782) / 38.745)
	=	1.14056	/	0.828081
	=	1.3774

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA	=	(IncomefromContinuingOperations_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(NetIncome_t - NonOperatingIncome_t	-	CashFlowsfromOperations_t)	/	TotalAssets_t
	=	(-16.037 - -0.068	-	-13.427)	/	27.241
	=	-0.093315

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Biolase has a M-score of -3.08 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →

What does a Beneish M-Score of 0.00 mean?

Biolase (BIOLQ) has a Beneish M-Score of 0.00 as of Jun. 25, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Biolase and its competitors.

Is Biolase's Beneish M-Score too high?

Biolase's current Beneish M-Score is 0.00. Overall, Biolase has a GF Score™ of 16/100, reflecting its overall financial health beyond just this single metric.

How does Biolase's Beneish M-Score compare to OPGN and AFIB?

Biolase's Beneish M-Score of 0.00 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Beneish M-Score for a Medical Devices & Instruments company?

A good Beneish M-Score depends on the Medical Devices & Instruments industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Beneish M-Score mean?

A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Biolase and its competitors. Biolase's current Beneish M-Score is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Biolase stock overvalued right now?

Biolase (BIOLQ) has a current Beneish M-Score of 0.00. The current Beneish M-Score is 0.00. Biolase's overall GF Score™ is 16/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Beneish M-Score calculated?

Beneish M-Score is calculated from a company's financial statements. For Biolase (BIOLQ), the current Beneish M-Score is 0.00 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biolase Business Description

Industry Healthcare Medical Devices & Instruments

Comparable Companies OPGN AFIB ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE PODD ZBH SHSE:688271 XSWX:SOON LSE:SN.TSE:7733 ASX:COH PEN

Address 27042 Towne Centre Drive, Suite 270, Lake Forest, CA, USA, 92610

Website https://www.biolase.com

Biolase Inc is a United States-based provider of laser systems for the dental industry. It develops, manufactures, markets, and sells laser systems in dentistry and medicine. The company offers two categories of laser system products: Waterlase (all-tissue) systems and Diode (soft-tissue) systems which allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a broad range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications. The majority of the company's revenue comes from the United States.

16GF Score

Get the complete analysis for BIOLQ

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00

Price

View BIOLQ Analysis

See Beneish M-Score data for all stocks →